Oncology Central

Could erlotinib be used in EGF receptor wild-type non-small-cell lung cancer?


The development of EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) has shifted our treatment paradigm in non-small-cell lung cancer (NSCLC). Erlotinib is an orally administered, first-generation, reversible EGFR TKI. The activating mutations in the tyrosine kinase domain of EGFR are considered to be the most important biomarkers to predict responses to erlotinib because these mutations are the oncologic drivers of some NSCLC by stimulating downstream signaling, such as the RAS–RAF–MEK–ERK, PI3K–AKT and STAT pathways. In the USA, erlotinib is the preferred front-line therapy in advanced EGFR-mutated NSCLC, with superior response rates and progression-free survival (PFS) in comparison to standard chemotherapy.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.